{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:19:26Z","timestamp":1790713166716,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Contezolid is a novel oxazolidinone, which exhibits potent activity against gram-positive bacteria, including methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA), vancomycin-resistant <jats:italic>Enterococcus<\/jats:italic> (VRE), and penicillin-resistant <jats:italic>Streptococcus pneumoniae<\/jats:italic> (PRSP). In this study, the <jats:italic>in vitro<\/jats:italic> activity of contezolid was compared with linezolid (LZD), tigecycline (TGC), teicoplanin (TEC), vancomycin (VA), daptomycin (DAP), and florfenicol (FFC) against MRSA and VRE strains isolated from China. Contezolid revealed considerable activity against MRSA and VRE isolates with MIC<jats:sub>90<\/jats:sub> values of 0.5 and 1.0 \u03bcg\/mL, respectively. For VRE strains with different resistance genotypes, including vanA- and vanM-type strains, contezolid did not exhibit significantly differential antibacterial activity. Furthermore, the antimicrobial activity of contezolid is similar to or slightly better than that of linezolid against MRSA and VRE strains. Subsequently, the activity of contezolid was tested against strains carrying linezolid resistance genes, including <jats:italic>Staphylococcus capitis<\/jats:italic> carrying <jats:italic>cfr<\/jats:italic> gene and <jats:italic>Enterococcus faecalis<\/jats:italic> carrying <jats:italic>optrA<\/jats:italic> gene. The results showed that contezolid exhibited similar antimicrobial efficacy to linezolid against strains with linezolid resistance genes. In general, contezolid may have potential benefits to treat the infections caused by MRSA and VRE pathogens.<\/jats:p>","DOI":"10.3389\/fmicb.2021.729900","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T17:46:41Z","timestamp":1629395201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China"],"prefix":"10.3389","volume":"12","author":[{"given":"Siheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5001\/omj.2019.37","article-title":"WHO global priority pathogens list: a bibliometric analysis of medline-pubmed for knowledge mobilization to infection prevention and control practices in Bahrain.","volume":"34","author":"Asokan","year":"2019","journal-title":"Oman Med. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.","volume":"71","author":"Barber","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2020.1750595","article-title":"Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials.","volume":"29","author":"Bassetti","year":"2020","journal-title":"Expert Opin. Investig. Drugs."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e01195","DOI":"10.1128\/AAC.01195-20","article-title":"In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against gram-positive clinical isolates from the United States and Europe.","volume":"64","author":"Carvalhaes","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B5","year":"","journal-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. CLSI Document M07-A8."},{"key":"B6","year":"","journal-title":"Performance Standards for Antimicrobial Susceptibility Testing. CLSI Document M100-S19."},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/jcm.33.1.24-27.1995","article-title":"Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.","volume":"33","author":"Dutka-Malen","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e02181","DOI":"10.1128\/AAC.02181-16","article-title":"Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects.","volume":"61","author":"Eckburg","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1021\/jm401931e","article-title":"New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.","volume":"57","author":"Gordeev","year":"2014","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus.","volume":"68","author":"Gu","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care.","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jhin.2017.10.006","article-title":"Validation of healthcare-associated infection surveillance in smaller Australian hospitals.","volume":"99","author":"Hoskins","year":"2018","journal-title":"J. Hosp. Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ijantimicag.2014.02.008","article-title":"Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I.","volume":"43","author":"Huang","year":"2014","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e01453","DOI":"10.1128\/AAC.01453-17","article-title":"Thrombocytopenia with tedizolid and linezolid.","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/AAC.01526-13","article-title":"In vivo antibacterial activity of MRX-I, a new oxazolidinone.","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.vetmic.2017.01.017","article-title":"Characterization of pig-associated methicillin-resistant Staphylococcus aureus.","volume":"201","author":"Li","year":"2017","journal-title":"Vet. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1124\/dmd.114.061747","article-title":"Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes.","volume":"43","author":"Meng","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/nyas.14254","article-title":"Molecular epidemiology and mechanisms of antibiotic resistance in Enterococcus spp., Staphylococcus spp., and Streptococcus spp. in Africa: a systematic review from a one health perspective.","volume":"1465","author":"Osei Sekyere","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8081155","article-title":"Mechanisms of linezolid resistance among enterococci of clinical origin in Spain-detection of optrA- and cfr(D)-carrying E. faecalis.","volume":"8","author":"Ruiz-Ripa","year":"2020","journal-title":"Microorganisms."},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.plasmid.2018.09.011","article-title":"Linezolid resistance genes and genetic elements enhancing their dissemination in enterococci and streptococci.","volume":"99","author":"Sadowy","year":"2018","journal-title":"Plasmid."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1517\/13543784.8.8.1195","article-title":"Mechanism of action of the oxazolidinone antibacterial agents.","volume":"8","author":"Shinabarger","year":"1999","journal-title":"Expert Opin. Investig. Drugs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3201\/eid1106.050156","article-title":"Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States.","volume":"11","author":"Stevenson","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1021\/acs.chemrestox.0c00524","article-title":"Nonclinical evaluation of antibacterial oxazolidinones contezolid and contezolid acefosamil with low serotonergic neurotoxicity.","volume":"34","author":"Wang","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/jac\/dkv116","article-title":"A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.","volume":"70","author":"Wang","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1128\/AAC.05827-11","article-title":"Distribution of the multidrug resistance gene cfr in Staphylococcus species isolates from swine farms in China.","volume":"56","author":"Wang","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2017.12.017","article-title":"Short-term safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy chinese subjects.","volume":"40","author":"Wu","year":"2018","journal-title":"Clin. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1128\/AAC.01710-09","article-title":"vanM, a new glycopeptide resistance gene cluster found in Enterococcus faecium.","volume":"54","author":"Xu","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: a promising option in the treatment of Gram-positives.","volume":"72","author":"Zahedi Bialvaei","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/s1471-4892(01)00082-0","article-title":"Oxazolidinones: a new class of antibacterials.","volume":"1","author":"Zurenko","year":"2001","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.729900\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T17:46:42Z","timestamp":1629395202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.729900\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":29,"alternative-id":["10.3389\/fmicb.2021.729900"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.729900","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"article-number":"729900"}}